• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Kymera Therapeutics' Broaden Phase 1B Atopic Dermatitis Trial Of KT-621 Achieved Deep STAT6 Degradation Across 100 mg And 200 mg Dose Groups, With Median Reductions Of 94% And 98% In Skin And Blood, Respectively

    Benzinga·12/08/2025 12:13:31
    Listen to the news
    • KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients
    • KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3, IL-31, IgE, and in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions
    • Robust clinical activity was observed across all disease endpoints measured including mean 63% EASI reduction and mean 40% peak pruritus NRS reduction for all patients
    • Patients with comorbid asthma showed a median 56% reduction in FeNO and meaningful improvements in asthma control, and those with comorbid allergic rhinitis experienced significant symptom and quality-of-life benefits
    • KT-621 was well-tolerated with no serious adverse events, no treatment related adverse events, no reported cases of conjunctivitis and no clinically relevant changes in vital signs, lab tests or ECGs
    • KT-621 BROADEN2 Phase 2b trial in moderate to severe AD is ongoing, with data expected by mid-2027; Phase 2b BREADTH trial in moderate to severe asthma patients is on track to start 1Q26